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SUMMARY
Background
Metabolic factors have been associated with liver damage in patients with
non-alcoholic fatty liver disease (NAFLD).
Aims
To test a new marker of adipose dysfunction, the visceral adiposity index
(VAI), in NAFLD patients to assess whether or not it is associated with host
factors, and to investigate a potential correlation with histological ﬁndings.
Methods
One hundred and forty-two consecutive NAFLD patients were evaluated by
liver biopsy, and clinical and metabolic measurements, including insulin
resistance with the homeostasis model assessment (HOMA), and VAI by
using waist circumference, body mass index, triglycerides and HDL. Serum
levels of TNFa, IL-6, adiponectin and leptin were also assessed. All biopsies
were scored for NAFLD activity score (NAS) and its components, and for
staging (Kleiner).
Results
By multiple linear regression analysis, VAI was independently associated
with higher HOMA (P = 0.04), and ﬁbrosis (P = 0.04). In addition, an inde-
pendent association was found between higher VAI and lower adiponectin
levels (P = 0.002). Higher HOMA (OR 1.149, 95% CI 1.003–1.316,
P = 0.04), higher VAI (OR 1.446, 95% CI 1.023–2.043, P = 0.03), lobular
inﬂammation (OR 3.777, 95% CI 1.771–8.051, P = 0.001), and ballooning
(OR 2.884, 95% CI 1.231–6.757, P = 0.01) were correlated with signiﬁcant
ﬁbrosis (F2–F4) on multiple logistic regression analysis. In particular, the
prevalence of signiﬁcant ﬁbrosis progressively increased from patients with a
VAI £ 2.1 and HOMA £ 3.4 (26%) to those with a VAI > 2.1 and
HOMA > 3.4 (83%).
Conclusions
In NAFLD patients, visceral adiposity index is an expression of both
qualitative and quantitative adipose tissue dysfunction and, together with
insulin resistance, is independently correlated with signiﬁcant ﬁbrosis.
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INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD), the hepatic
manifestation of insulin resistance (IR), is a leading
cause of chronic liver disease worldwide.1, 2 A relevant
proportion of NAFLD patients, particularly those with
non-alcoholic steatohepatitis (NASH), may progress to
cirrhosis and its complications,1, 3 with liver necroin-
ﬂammation4, 5 and IR5, 6 the strongest predictors of
both severity of ﬁbrosis, and progression of liver dis-
ease.
There has been increasing interest in the last few years
in the role of visceral adipose tissue in both cardiometa-
bolic disorders and NAFLD. In fact, studies have shown
that visceral adipose tissue, originally considered a pas-
sive depot for energy storage, is able to secrete a variety
of substances that regulate metabolism, inﬂammation
and immunity, participating in the pathogenesis of the
above-cited disorders.7, 8 Visceral adiposity, when evalu-
ated by magnetic resonance, the best estimation of vis-
ceral obesity, correlates with liver-fat accumulation in
healthy subjects,9, 10 and with severity of both inﬂamma-
tion and ﬁbrosis in NASH.11 The association between
visceral obesity, evaluated using waist circumference
(WC) measurement – a surrogate marker of visceral adi-
posity, and liver damage in terms of both the presence
of steatosis and disease progression, has also been found
in other studies on NAFLD and chronic hepatitis C
(CHC).12–15 However, in most of these studies, the effect
of visceral obesity on the histological features of the liver
disease was not corrected for IR. In addition, the use of
WC to indicate visceral obesity is not entirely accurate,
because WC alone does not help in distinguishing
between subcutaneous and visceral fat mass,16 the latter
being the key factor in the development of metabolic
alteration.
To overcome these problems, a recent study17 elabo-
rated an index, using both anthropometric [body mass
index (BMI) and WC] and metabolic (TG and HDL)
parameters. This index, called the visceral adiposity index
(VAI), is thought to be capable of indicating both fat
distribution and function, and has been proposed as a
surrogate marker of adipose tissue dysfunction. VAI has
been independently correlated with cardiometabolic risk
in general population,17 and with severity of both steato-
sis and necroinﬂammatory activity in patients with geno-
type 1 (G1) CHC.18 In light of these facts, we aimed to
assess the host factors associated with VAI, and its asso-
ciation with histological features in patients with a histo-
logical diagnosis of NAFLD.
MATERIALS AND METHODS
Patients
One hundred and forty-two consecutive patients with
NAFLD, recruited at the Gastrointestinal & Liver Unit at
the University Hospital in Palermo and fulﬁlling all
inclusion and exclusion criteria detailed below were
assessed. Patients were included if they had a histological
diagnosis of NAFLD by liver biopsy done less than
6 months before enrolment. The diagnosis of NAFLD
was based on chronically elevated ALT for at least
6 months, alcohol consumption of <20 g ⁄day in the year
before liver biopsy and evaluated by a questionnaire, and
steatosis (>5% of hepatocytes) at histology with ⁄without
necroinﬂammation and ⁄or ﬁbrosis. Exclusion criteria
were: (i) advanced cirrhosis; (ii) hepatocellular carci-
noma; (iii) other causes of liver disease or mixed aetiolo-
gies (excessive alcohol consumption, hepatitis C, hepatitis
B, autoimmune liver disease, Wilson’s disease, hemochro-
matosis, a1-antitrypsin deﬁciency); (iv) human immuno-
deﬁciency virus infection; (v) previous treatment with
anti-viral therapy, immunosuppressive drugs and ⁄or reg-
ular use of steatosis-inducing drugs, evaluated by inter-
view; (vi) therapy with medications known to affect UA
metabolism, or; (vii) active intravenous drug addiction.
The study was carried out in accordance with the
principles of the Declaration of Helsinki and its appendi-
ces, and with local and national laws. Approval was
obtained from the hospital’s Internal Review Board and
its Ethics Committee, and written informed consent was
obtained from all patients and controls.
Clinical and laboratory assessment
Clinical and anthropometric data were collected at the
time of liver biopsy. Body mass index (BMI) was calcu-
lated on the basis of weight in kilograms and height in
metres, and patients were classiﬁed as normal weight
(BMI, 18.5–24.9 kg ⁄m2), overweight (BMI, 25–29.9), or
obese (BMI ‡30). Waist circumference was measured at
the midpoint between the lower border of the rib cage
and the iliac crest. A diagnosis of arterial hypertension
was based on the following criteria: systolic blood pres-
sure ‡135 mmHg and ⁄or diastolic blood pressure
‡85 mmHg (measured three times in 30 min, in the sit-
ting position and using a brachial sphygmomanometer),
or use of blood-pressure-lowering agents. A diagnosis of
type 2 diabetes was based on the revised criteria of the
American Diabetes Association, using a value of fasting
blood glucose ‡126 mg ⁄dL on at least two occasions.19
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In patients with a previous diagnosis of type 2 diabetes,
current therapy with insulin or oral hypoglycaemic
agents was documented. Metabolic syndrome was diag-
nosed according to ATPIII criteria.20
A 12 h overnight fasting blood sample was drawn at
the time of biopsy to determine serum levels of ALT,
GGT, total cholesterol, HDL cholesterol, triglycerides,
plasma glucose concentration, insulin and platelet count.
Insulin resistance (IR) was determined by the homeosta-
sis model assessment (HOMA) method, using the follow-
ing equation:21 insulin resistance (HOMA-IR) = fasting
insulin (lU ⁄mL) · fasting glucose (mmol ⁄L) ⁄22.5.
HOMA-IR has been validated in comparison with the
euglycaemic ⁄hyperinsulinemic clamp technique in both
diabetic and nondiabetic patients.22 The VAI was calcu-
lated as previously described,17 using the following gen-
der-speciﬁc equations, where TG is triglyceride levels
expressed in mmol ⁄L and HDL is HDL-cholesterol levels



















Serum TNFa (GE Healthcare Amersham TNF-a:
Human, Biotrak Easy ELISA, Piscataway, USA), IL-6
(Human IL-6b ultrasensitive singleplex Bead Kit, Invitro-
gen Camarillo, California, USA), adiponectin (SPIbio –
Bertin Pharma Human Adiponectin EIA Kit), and leptin
(CAYMAN – EIA kit leptin human, Atlanta, Georgia) lev-
els were measured in duplicate in a subgroup of patients.
Histology
Slides were coded and read by one pathologist (D.C.),
who was unaware of the patient’s identity and history. A
minimum length of 15 mm of biopsy specimen or the
presence of at least 10 complete portal tracts was
required.23 Steatosis was assessed as the percentage of
hepatocytes containing fat droplets (minimum 5%), and
evaluated as a continuous variable. The Kleiner classiﬁca-
tion24 was used to compute the NAS score (from 0 to 8,
on a scale including separate scores for steatosis, lobular
inﬂammation, and hepatocellular ballooning), and to
stage ﬁbrosis from 0 to 4.
Statistics
Continuous variables were summarised as mean  s.d.,
and categorical variables as frequency and percentage.
The Student’s t-test and Chi-squared test were used
when appropriate. Multiple linear regression analysis was
done to identify independent predictors of VAI as the
continuous dependent variable. As candidate risk factors,
we selected age, gender, BMI, WC, baseline ALT, platelet
count levels, triglycerides, total and HDL cholesterol,
blood glucose, insulin, HOMA score, adipocytokines (in
patients for whom these data were available), diabetes,
arterial hypertension, metabolic syndrome, steatosis, lob-
ular inﬂammation, ballooning, NAS score, and ﬁbrosis.
Multiple logistic regression models were used to
assess the relationship of NAS score and ﬁbrosis to the
demographic, metabolic and histological characteristics
of patients. In the ﬁrst model, the dependent variable
was NAS score, coded as 1 = NAS ‡5 vs. 0 = NAS <5.
In the second model, the dependent variable was signif-
icant ﬁbrosis coded as 1 = present (F2–F4) vs.
0 = absent (F0–F1). As candidate risk factors, we
selected the same independent variables included in the
linear model, and added the VAI score as an additional
independent variable.
Variables associated with the dependent variable on
univariate analysis (probability threshold, P £ 0.10) were
included in the multivariate regression models. To avoid
the effect of colinearity, diabetes, IR, HOMA score, blood
glucose levels and insulin levels, as well as waist circum-
ference, BMI, HDL cholesterol, triglycerides, metabolic
syndrome and VAI score, or the NAS score and its com-
ponents, were not included in the same multivariate
model. Regression analyses were done using Proc Logis-
tic, Proc Reg and subroutine in SAS (SAS Institute, Inc.,
Cary, NC, USA).25
RESULTS
Patient characteristics and histology
The baseline characteristics of the 142 patients are shown
in Table 1. The majority of our patients were in the
overweight to obesity range, and nearly a quarter were
hypertensive. Diabetes was present in about 15% of
patients, and metabolic syndrome was diagnosed in 30%
of patients. Using the Kleiner criteria (24), at liver biopsy
65% of NAFLD were classiﬁed as NASH, 9% as non-
NASH, and 26% were indeterminate. One patient in
three had steatosis of >66%, and half the number of
patients had ﬁbrosis ‡2.
In the 111 patients whose serum samples were avail-
able, and comparable to the entire population (76 male
patients; mean age 45.6  12.5 years; mean HOMA
4.35  3.54; mean VAI 2.33  1.50 mg ⁄dL; 66% with
Visceral adiposity index and NAFLD
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NAS ‡ 5; and 47% with ﬁbrosis ‡2), serum levels of
TNFa, IL-6, adiponectin and leptin were measured. The
mean TNFa serum level was 7.2  3.9 pg ⁄mL (range 1–
16.4), the mean IL-6 serum level was 2.44  1.67 fg ⁄mL
(range 0.13–8.29), the mean adiponectin serum level
was 5.47  2.16 lg ⁄mL (range 2–13.6), and the mean
leptin serum level was 15.35  14.95 ng ⁄mL (range
0.2–73.2).
Factors associated with VAI score
The mean VAI was 2.41. Older age (P = 0.03), male gen-
der (P = 0.03), high blood glucose (P = 0.01), high insu-
lin (P < 0.001), high HOMA score (P < 0.001), presence
of metabolic syndrome (P < 0.001), hepatocellular bal-
looning (P = 0.03), lobular inﬂammation (P = 0.001),
NAS score (P = 0.001) and ﬁbrosis (P < 0.001), were
associated with higher VAI in NAFLD, although only
higher HOMA (P = 0.04), and ﬁbrosis (P = 0.04) were
independent factors on multiple linear regression analysis
(Table 2).
Table 1 | Baseline demographic, laboratory, metabolic
and histological characteristics of 142 patients with
non-alcoholic fatty liver disease
Variable
Non-alcoholic fatty
liver disease (n = 142)
Mean Age – years 45.4  13.0
Gender
Male vs. female 95 (66.9) ⁄47 (33.1)
Mean Body Mass Index – kg ⁄m2 30.1  4.7




Waist circumference (cm) 100.7  13.1
Arterial hypertension
Absent ⁄ present 112 (78.9) ⁄ 30 (21.1)
Type 2 diabetes
Absent ⁄ present 119 (83.8) ⁄23 (16.2)
Metabolic syndrome
Absent ⁄ present 98 (60.1) ⁄44 (30.9)
Alanine aminotransferase – IU ⁄ L 77.5  49.0
Platelet Count – 103 · mmc 220.4  62.2
c-glutamil transferase – IU ⁄ L 117.0  229.8
Cholesterol – mg ⁄ dL 204.4  47.6
HDL Cholesterol – mg ⁄ dL 48.1  15.8
LDL Cholesterol – mg ⁄ dL 126.0  39.8
Triglycerides – mg ⁄ dL 151.6  73.9
Blood glucose – mg ⁄ dL 98.9  28.8
Insulin – lU ⁄mL 17.7  10.5
HOMA 4.52  3.77
VAI 2.41  1.55
Leptin ng ⁄mL* 15.35  14.95
Adiponectin lg ⁄mL* 5.47  2.16
Tumour necrosis factor-a pg ⁄mL* 7.20  3.90
Interleukin-6 fg ⁄mL* 2.44  1.67
Histology at biopsy
Steatosis as continuous
variable (percent of total cells)
46.3  25.4
Steatosis grade
1 (5–33%) 50 (35.2)
2 (>33–66%) 45 (31.7)
3 (>66%) 47 (33.1)
Hepatocellular ballooning
0 8 (5.6)
Table 1 | (Continued)
Variable
Non-alcoholic fatty


















IU, international units; HOMA, homeostasis model assess-
ment; HDL, high density lipoprotein; LDL, low density lipopro-
tein; VAI, visceral adiposity index.
Data are given as mean  standard deviation or as number of
case (%).
* Data are relative to 111 patients.
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In the 111 patients assessed for adipocytokines, VAI
was linked to older age (P = 0.01), high blood glucose
(P = 0.08), high insulin (P = 0.009), high HOMA
(P = 0.002), low adiponectin (P = 0.002), metabolic syn-
drome (P < 0.001), lobular inﬂammation (P = 0.003),
NAS score (P = 0.08) and ﬁbrosis (P = <0.001), although
only lower adiponectin level (b )0.285; S.E. 0.062;
P = 0.002) and ﬁbrosis (b 0.240; S.E. 0.129; P = 0.02)
were independent factors on multiple linear regression
analysis. No signiﬁcant associations were found between
VAI and TNFa, IL-6 and leptin levels.
Characteristics of the entire population according to
VAI quintiles are shown in Table S1. Figure 1 shows
serum adiponectin distribution according to quintiles of
VAI.
Factors associated with histological features
The univariate and multivariate comparisons of variables
between patients with and without signiﬁcant ﬁbrosis
(F2-F4) are reported in Table 3. Multivariate logistic
regression analysis showed that the following features
were independently linked to signiﬁcant ﬁbrosis (F2–F4):
higher HOMA (OR 1.149, 95% CI 1.003–1.163,
P = 0.04), higher VAI (OR 1.446, 95% CI 1.023–2.043,
P = 0.03), hepatocellular ballooning (OR 2.884, 95% CI
1.231–6.757, P = 0.01) and lobular inﬂammation (OR
3.777, 95% CI 1.771–8.051, P = 0.001). Figure 2a shows
the distribution of VAI according to signiﬁcant ﬁbrosis.
The ROC curve analysis identiﬁed a VAI of >2.10 (sen-
sitivity 69%, speciﬁcity 70%; AUC 0.715) and a HOMA
score of > 3.40 (sensitivity 68%, speciﬁcity 66%; AUC
Table 2 | Univariate and multivariate analysis of factors associated with visceral adiposity index as continuous variable
in 142 patients with non-alcoholic fatty liver disease
Variable
Univariate Analysis Multivariate Analysis
B S.E. P value b S.E. P value
Mean Age – years 0.178 0.010 0.03 0.041 0.010 0.63
Male Gender 0.173 0.274 0.03 0.071 0.274 0.39
Mean Body Mass Index – kg ⁄m2 0.183 0.027 0.02 –
Waist Circumference (cm) 0.230 0.010 0.006 –
Alanine Aminotransferase – IU ⁄ L 0.139 0.003 0.10 –
c-glutamyl transferase 0.071 0.001 0.39 –
Cholesterol – mg ⁄ dL 0.370 0.003 <0.001 –
HDL cholesterol – mg ⁄ dL )0.486 0.007 <0.001 –
LDL cholesterol – mg ⁄ dL 0.303 0.003 <0.001 –
Triglycerides – mg ⁄ dL 0.896 0.001 <0.001 –
Platelet count – 103 · mmc )0.101 0.002 0.37 –
Blood glucose – mg ⁄ dL 0.209 0.004 0.01 –
Insulin – lU ⁄mL 0.344 0.012 <0.001 –
HOMA 0.309 0.033 <0.001 0.134 0.037 0.04
Diabetes 0.118 0.352 0.16 –
Arterial hypertension 0.137 0.317 0.10 –
Metabolic syndrome 0.651 0.215 <0.001 –
Histology at biopsy
Steatosis as continuous variable 0.082 0.005 0.33 –
Steatosis grade 0.061 0.158 0.47 –
Hepatocellular ballooning 0.179 0.202 0.03 –
Lobular inflammation 0.279 0.186 0.001 –
NAFLD activity score (NAS) 0.206 0.084 0.001 0.047 0.091 0.60
Stage of fibrosis 0.337 0.103 <0.001 0.201 0.129 0.04
b, b coefficient; S.E., standard error of b; IU, international units; HOMA, homeostasis model assessment.
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0.756) as the best cut-offs for predicting signiﬁcant ﬁbro-
sis. It is noteworthy that by combining these two non-
invasive classes of variables, the prevalence of signiﬁcant
ﬁbrosis progressively increased from patients in the best
class (VAI £ 2.1 and HOMA £ 3.4, signiﬁcant ﬁbrosis in
12 ⁄46, 26%), to those with only one positive predictor
(VAI £ 2.1 and HOMA > 3.4, signiﬁcant ﬁbrosis in
10 ⁄26, 38%; VAI > 2.1 and HOMA £ 3.4, signiﬁcant
ﬁbrosis in 11 ⁄24, 46%), and further to those in the worst
class (VAI > 2.1 and HOMA > 3.4, signiﬁcant ﬁbrosis in
38 ⁄46, 83%) (Figure 2b). The positive predictive value of
both VAI > 2.1 and HOMA > 3.4 for the diagnosis of sig-
niﬁcant ﬁbrosis was 83%, whereas the negative predictive
value of both VAI £ 2.1 and HOMA £ 3.4 for the exclu-
sion of signiﬁcant ﬁbrosis was 74%.
Considering adipocytokine levels, no association was
found between signiﬁcant ﬁbrosis and TNFa
(7.03  3.99 vs. 7.51  4.02; P = 0.52), IL-6
(2.23  1.83 vs. 2.69  1.43; P = 0.14), adiponectin
(5.80  2.40 vs. 5.03  1.69; P = 0.06) and leptin
(12.81  15.58 vs. 18.23  13.80; P = 0.06) levels.
The univariate and multivariate comparisons of vari-
ables between patients with NAS score ‡5 and those with
a NAS score of <5 are reported in Table S2. Multivariate
logistic regression analysis showed that the following fea-
tures were independently linked to a NAS score ‡5:
higher ALT levels (OR 1.011, 95% CI 1.001–1.022,
P = 0.02), and higher HOMA (OR 1.187, 95% CI 1.005–
1.402, P = 0.04).
DISCUSSION
In a cohort of patients with a histological diagnosis of
NAFLD, we found that VAI is an expression of adipose
tissue dysfunction. In addition, we found that this index
was associated not only with IR, but, together with IR,
was also independently correlated with the severity of
liver ﬁbrosis.
Data in the literature suggest that VAI appears able to
indirectly indicate both fat distribution and function in
non-obese, healthy patients and in primary care
patients.17 Therefore, this index reﬂects other nonclassic
cardiometabolic risk factors, such as altered production
of adipocytokines ⁄ cytokines, increased lipolysis and
plasma free fatty acids, which are not signiﬁed by BMI,
WC, TG and HDL separately.17
In this study we conﬁrmed the association between
VAI and IR in NAFLD patients, previously reported also
in healthy patients,17 in primary care patients,17 and in
G1 CHC patients,18 and have speculated on the ability of
adipose tissue to directly participate in IR pathogenesis.
This is, to the best of our knowledge, the ﬁrst reported
ﬁnding of a linear, independent association between a
higher VAI and lower adiponectin levels. This data is of
particular interest because this is the ﬁrst study to evalu-
ate the potential association between VAI and adipocyto-
kine imbalance as an expression of adipose tissue
dysfunction. Interestingly, we also conﬁrmed the hypoth-
esis that VAI is an expression not only of fat distribu-
tion, but also of adipose tissue dysfunction,
demonstrated by the inverse relation between VAI and
adiponectin levels observed in our NAFLD patients. In
fact, it is well known that inﬂamed adipose tissue leads
to different changes in the systemic adipocytokine envi-
ronment, also characterised by a lower adiponectin pro-
duction.7
The assessment of liver ﬁbrosis is crucial for the prog-
nostic evaluation of NAFLD patients, particularly in
those without advanced disease, but at risk of developing
cirrhosis, like those with signiﬁcant ﬁbrosis. In this line
different studies evaluated factor directly or indirectly
affecting liver ﬁbrosis severity in NAFLD,26 and other
studies focused on the development of non-invasive tools
to predict the stage of ﬁbrosis in these patients.27, 28 In
particular it is possible to discriminate between direct or
indirect serum markers, aimed at predicting ﬁbrosis stage
using clinical features and parameters measurable in
serum,27, 28 and methodologies derived from elaboration
of parameters obtainable with the current liver imaging
techniques [ultrasound, computed tomography (CT)
scan, magnetic resonance] or to the innovative use of
principles of physics like ﬁbroscan.27–29
A novel ﬁnding of this study is that signiﬁcant ﬁbrosis
is independently associated not only with IR and lobular
Distributi n of adipon ctin serum levels 
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Figure 1 | Distribution of adiponectin serum levels
according to VAI quintiles.
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inﬂammation, two well-known risk factors for ﬁbrosis in
NAFLD,4–6 but also with VAI. Other studies have found
a direct association between visceral adipose tissue, eval-
uated by magnetic resonance, and severity of ﬁbrosis.11
Similarly, a recent Asian prospective study identiﬁed vis-
ceral obesity, evaluated by WC, as a predictor of ﬁbrosis
progression in NAFLD patients.30 However, these studies
did not correct for the presence of IR and its effect on
Table 3 | Univariate and multivariate analysis of risk factors associated with significant fibrosis (F2–F4) in 142 patients












OR (95% CI) P value
Age – years 41.7  10.8 49.2  14.0 0.001 1.017 (0.983–1.053) 0.33
Gender
Male vs. Female 55 ⁄ 16 40 ⁄ 31 0.007 1.117 (0.448–2.787) 0.81
Body Mass Index – kg ⁄m2 28.9  5.0 31.4  4.1 0.002 –
Waist circumference-cm 98.1  13.2 103.4  12.5 0.01 –
Alanine Aminotransferase – IU ⁄ L 77.5  48.5 77.5  49.8 0.99 –
Platelet count – 103 · mmc 223.8  53.2 217.0  70.2 0.52 –
c-glutamyl transferase – IU ⁄ L 127.2  288.9 106.7  150.8 0.59 –
Cholesterol – mg ⁄ dL 205.6  43.6 203.2  51.6 0.75 –
HDL cholesterol – mg ⁄ dL 52.1  17.7 44.0  12.5 0.002 –
LDL cholesterol – mg ⁄ dL 126.6  34.8 125.4  44.5 0.86 –
Triglycerides – mg ⁄ dL 134.9  69.6 168.7  74.5 0.006 –
Blood glucose – mg ⁄ dL 94.1  24.2 103.7  32.2 0.04 –
Insulin – lU ⁄mL 13.7  7.6 21.7  11.4 <0.001 –
HOMA 3.31  2.90 5.74  4.15 <0.001 1.149 (1.003–1.316) 0.04
Arterial hypertension
Absent ⁄ present 60 ⁄ 11 52 ⁄ 19 0.10 –
Type 2 diabetes
Absent ⁄ present 65 ⁄6 54 ⁄ 17 0.01 –
Metabolic syndrome
Absent ⁄ present 59 ⁄ 12 39 ⁄ 32 <0.001 –
VAI 1.86  1.21 2.96  1.66 <0.001 1.446 (1.023–2.043) 0.03
Histology at biopsy
Steatosis as continuous variable 40.5  27.0 52.1  22.4 0.006 1.010 (0.992–1.029) 0.28
Steatosis grade
1 ⁄2 ⁄ 3 31 ⁄ 21 ⁄ 18 18 ⁄ 24 ⁄29 0.01 –
Hepatocellular ballooning
0 ⁄ 1 ⁄2 8 ⁄ 33 ⁄ 30 0 ⁄29 ⁄52 <0.001 2.884 (1.231–6.757) 0.01
Lobular inflammation
0 ⁄ 1 ⁄2 ⁄ 3 10 ⁄43 ⁄ 18 ⁄0 0 ⁄ 23 ⁄43 ⁄5 <0.001 3.777 (1.771–8.051) 0.001
NAFLD activity score (NAS)
0–2 ⁄ 3–4 ⁄5–8 12 ⁄28 ⁄ 31 1 ⁄9 ⁄61 <0.001 –
IU, international units; HOMA, homeostasis model assessment; HDL, high density lipoprotein; LDL, low density lipoprotein; VAI,
visceral adiposity index.
Data are given as mean  standard deviation or as number of case (%).
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obesity. In addition, other studies have also found a link
between severity of ﬁbrosis in NAFLD and a cytokine
imbalance, characterised by an increase in proinﬂamma-
tory mediators and a decrease in anti-inﬂammatory
mediators.31–37 We have provided the ﬁrst evidence in
NAFLD of an independent link between liver ﬁbrosis
and an index of adipose dysfunction (VAI) that takes
into account both quantitative and qualitative alterations
of visceral adipose tissue, also correcting for IR. It is
worth emphasising that in our study both IR and a high
VAI score were independently associated with ﬁbrosis,
leading to a hypothesis on the ability of adipose tissue to
interfere with ﬁbrogenesis mechanisms not only through
IR, but also through its well-known function as an endo-
crine organ able to modulate metabolic functions, includ-
ing ﬁbrogenesis.7, 31
From a clinical standpoint, a VAI at a threshold of
2.1, and HOMA at a threshold of 3.4, if combined, can
identify patients at a high or a low risk of signiﬁcant
ﬁbrosis. In particular, three groups of patients can be
identiﬁed: one with no predictors and a rate of signiﬁ-
cant ﬁbrosis of about 25%; a second, with at least one
predictor and a rate of signiﬁcant ﬁbrosis that ranges
from 38% to 45%; and a third, with all predictors, and
a rate of signiﬁcant ﬁbrosis of more than 80%. These
ﬁndings would seem to suggest using VAI and HOMA
as a way of reducing the number of liver biopsies for
staging NAFLD ﬁbrosis, even if, clearly, furthermore
studies must be done, to conﬁrm our data in diverse
patient populations and in larger cohorts of patients,
before applying this method in clinical practice. In addi-
tion, it should be interesting to investigate the combina-
tion of these surrogate markers with liver elastography
for a possible increase in diagnostic accuracy of the
assessment of liver ﬁbrosis. Our study might also sug-
gest VAI as an indicator of adipose-related liver damage,
though prospective studies evaluating VAI as predictor
of liver disease progression, and as a new therapeutic
outcome in the management of NAFLD patients, are
needed.
We found no association among NAS score, expres-
sion of the activity of NAFLD and VAI, although we
conﬁrmed IR, a well-known risk factor for NASH,4 as
independently associated with a NAS score suggesting
NASH diagnosis. Therefore, we posit an indirect role of
VAI on liver NASH activity through reduction of insulin
sensitivity.
The main limitation of this study lies in its cross-sec-
tional nature, making it impossible to dissect the tempo-
ral relation among IR, VAI and ﬁbrosis in NAFLD
patients. A further methodological question is the poten-
tially limited external validity of the results for different
populations and settings. Our study included a cohort of
Italian patients enrolled at a tertiary care centre, who
may be different from the majority of cases of NAFLD
in the general population. Lack of data on the serum lev-
els of other adipocytokines, and on adipose expression of
proinﬂammatory cytokines and adipocytokines may also
have affected interpretation of the results.
In conclusion, we conﬁrmed the hypothesis that VAI
is a new index of both fat function and distribution, and
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Figure 2 | (a) Distribution of VAI according to the pres-
ence or absence of significant fibrosis (F2–F4) in
patients with non-alcoholic fatty liver disease. (b) Prev-
alence of significant fibrosis (F2–F4) according to spe-
cific patterns of predictors. VAI £ 2.1 and HOMA £ 3.4;
VAI £ 2.1 and HOMA > 3.4; VAI > 2.1 and HOMA £ 3.4;
VAI > 2.1 and HOMA > 3.4.
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signiﬁcant ﬁbrosis in NAFLD patients. These data need
furthermore validation in independent, large scale stud-
ies, although they seem to suggest an evaluation of this
score as a new therapeutic outcome in the management
of NAFLD patients.
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